These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22122458)

  • 1. Effects of PPARγ ligands on vascular tone.
    Salomone S; Drago F
    Curr Mol Pharmacol; 2012 Jun; 5(2):282-91. PubMed ID: 22122458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
    Polikandriotis JA; Mazzella LJ; Rupnow HL; Hart CM
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1810-6. PubMed ID: 16020752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
    Zhou YB; Zhang J; Peng DQ; Chang JR; Cai Y; Yu YR; Jia MZ; Wu W; Guan YF; Tang CS; Qi YF
    Cell Biochem Biophys; 2013 Jul; 66(3):421-9. PubMed ID: 23274912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
    Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
    Ciudin A; Hernandez C; Simó R
    Curr Top Med Chem; 2012; 12(6):585-604. PubMed ID: 22242856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
    Osman I; Segar L
    Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N; Walcher D
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells.
    Ikeda U; Shimpo M; Murakami Y; Shimada K
    Hypertension; 2000 Jun; 35(6):1232-6. PubMed ID: 10856269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
    Banerjee PS; Samanta S
    Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension.
    Chang L; Villacorta L; Zhang J; Garcia-Barrio MT; Yang K; Hamblin M; Whitesall SE; D'Alecy LG; Chen YE
    Circulation; 2009 Apr; 119(16):2161-9. PubMed ID: 19364979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protective role of PPARgamma agonists against cardiovascular disease].
    Yamagishi S
    Nihon Rinsho; 2010 Feb; 68(2):307-11. PubMed ID: 20158101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.